155 related articles for article (PubMed ID: 33604941)
1. Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study.
Hata T; Hagihara K; Tsutsui A; Akamatsu H; Ohue M; Shingai T; Tei M; Ikenaga M; Kim HM; Osawa H; Takemoto H; Konishi K; Uemura M; Matsuda C; Mizushima T; Murata K; Ohno Y; Doki Y; Eguchi H
Oncologist; 2021 May; 26(5):e735-e741. PubMed ID: 33604941
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
Kosugi C; Koda K; Takiguchi N; Takaishi S; Miyauchi H; Hirayama N; Nomura Y; Kondo E; Kawasaki Y; Ozawa Y; Matsubara H
Int J Colorectal Dis; 2021 Aug; 36(8):1739-1749. PubMed ID: 33715077
[TBL] [Abstract][Full Text] [Related]
3. A prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study.
Okuda H; Shimomura M; Ikeda S; Nakahara M; Miguchi M; Ishizaki Y; Saitoh Y; Toyota K; Sumitani D; Shimizu Y; Takakura Y; Shimizu W; Yoshimitsu M; Kodama S; Fujimori M; Oheda M; Kobayashi H; Ohdan H;
Cancer Chemother Pharmacol; 2023 Apr; 91(4):317-324. PubMed ID: 36947210
[TBL] [Abstract][Full Text] [Related]
4. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
7. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
[TBL] [Abstract][Full Text] [Related]
8. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
11. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Yu YL; Tseng WK; Liao CK; Yeh CY; Chen HH; Liu YH; Liaw YW; Fan CW
BMC Cancer; 2023 Sep; 23(1):900. PubMed ID: 37749535
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
[TBL] [Abstract][Full Text] [Related]
13. Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients.
Meguro M; Furuhata T; Okita K; Nishidate T; Ishiyama G; Iwayama Y; Kimura Y; Mizuguchi T; Hirata K
Int J Clin Oncol; 2009 Oct; 14(5):402-7. PubMed ID: 19856047
[TBL] [Abstract][Full Text] [Related]
14. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Mochizuki I; Takiuchi H; Ikejiri K; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Takahashi Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Matsubara Y; Sugihara K
Br J Cancer; 2012 Mar; 106(7):1268-73. PubMed ID: 22415232
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Chemotherapy With UFT/LV
Ogawa H; Shiraishi T; Okada T; Miyamae Y; Motegi Y; Shirabe K; Saeki H
Anticancer Res; 2024 Feb; 44(2):805-814. PubMed ID: 38307591
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
20. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Hsu TC; Wang CC
J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
